AIDX
20/20 Biolabs, Inc. Common StockNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$20.90M
P/E Ratio
—
EPS
$-0.36
Beta
-0.42
52W High
$50.00
52W Low
$1.51
50-Day MA
$4.00
200-Day MA
$4.00
Dividend Yield
—
Profit Margin
-182.80%
Forward P/E
—
PEG Ratio
—
About 20/20 Biolabs, Inc. Common Stock
20/20 Biolabs, Inc. (ticker: AIDX) is a biotechnology company focused on providing innovative solutions for genomic research and diagnostics. The company specializes in delivering advanced laboratory services that enhance the accuracy and efficiency of genetic testing, catering to both clinical and research markets. With a commitment to leveraging cutting-edge technologies, 20/20 Biolabs aims to redefine the standards of molecular diagnostics and contribute significantly to the advancement of personalized medicine. As the demand for genomic data continues to rise, the company's strategic initiatives position it well for growth in this rapidly evolving sector.
Fundamentals
| Revenue (TTM) | $2.05M |
| Gross Profit (TTM) | 604,540 |
| EBITDA | $-3.25M |
| Operating Margin | -169.60% |
| Return on Equity | -503.00% |
| Return on Assets | -53.90% |
| Revenue/Share (TTM) | $0.41 |
| Book Value | $0.01 |
| Price-to-Book | 317.43 |
| Price-to-Sales (TTM) | 10.22 |
| EV/Revenue | 9.62 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.40% |
| Shares Outstanding | $10.35M |
| Float | $9.00M |
| % Insiders | 30.45% |
| % Institutions | 0.00% |
Data last updated: 4/7/2026